New alternative anticoagulants in atrial fibrillation

The move beyond warfarin

Ashish A. Bhimani, Mauricio Hong

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Given the increasing prevalence of atrial fibrillation, the need for safe and effective stroke prophylaxis will continue to rise. Warfarin has been around for many years and has proven efficacy in preventing stroke, but it has major limitations due to its variable dosing, food and drug interactions, and requirement for regular monitoring. Newer agents which include dabigatran, rivaroxaban, and apixaban have recently or will soon be available and may provide an improved efficacy in stroke prevention, an improved safety profile, and improved user-friendliness. Dabigatran was the first of the agents to be widely available, and in the RE-LY study, dabigatran (150 mg dose) showed superiority to warfarin in preventing ischemic stroke and a significant reduction in intracranial bleeding. Rivaroxaban was studied in the ROCKETAF trial, and with once daily dosing, it showed noninferiority to warfarin in preventing stroke with a significant reduction in intracranial bleeding. The ARISTOTLE trial showed apixaban was superior to warfarin for stroke prevention, significantly reduced all major bleeding, and resulted in a significant reduction in all-cause mortality. While all three trials have important limitations, they were very large randomized trials with more than 14,000 patients each and show a clear overall net clinical benefit when compared with warfarin. Key features of the drugs as well as an individual's preferences and stability on warfarin will help guide the ultimate drug choice for any given patient, but these newer anticoagulant agents are likely to usher in a new era in stroke prevention in atrial fibrillation.

Original languageEnglish (US)
Pages (from-to)78-85
Number of pages8
JournalReviews on Recent Clinical Trials
Volume8
Issue number2
DOIs
StatePublished - 2013
Externally publishedYes

Fingerprint

Warfarin
Anticoagulants
Atrial Fibrillation
Stroke
Hemorrhage
Food-Drug Interactions
Pharmaceutical Preparations
Safety
Mortality
Dabigatran

Keywords

  • Anticoagulation
  • Apixaban
  • Atrial fibrillation
  • Dabigatran
  • Intracranial hemorrhage
  • Rivaroxaban
  • Stroke
  • Warfarin

ASJC Scopus subject areas

  • Medicine(all)
  • Pharmacology

Cite this

New alternative anticoagulants in atrial fibrillation : The move beyond warfarin. / Bhimani, Ashish A.; Hong, Mauricio.

In: Reviews on Recent Clinical Trials, Vol. 8, No. 2, 2013, p. 78-85.

Research output: Contribution to journalArticle

Bhimani, Ashish A. ; Hong, Mauricio. / New alternative anticoagulants in atrial fibrillation : The move beyond warfarin. In: Reviews on Recent Clinical Trials. 2013 ; Vol. 8, No. 2. pp. 78-85.
@article{03a36fa1223c421eb8d1067e871da722,
title = "New alternative anticoagulants in atrial fibrillation: The move beyond warfarin",
abstract = "Given the increasing prevalence of atrial fibrillation, the need for safe and effective stroke prophylaxis will continue to rise. Warfarin has been around for many years and has proven efficacy in preventing stroke, but it has major limitations due to its variable dosing, food and drug interactions, and requirement for regular monitoring. Newer agents which include dabigatran, rivaroxaban, and apixaban have recently or will soon be available and may provide an improved efficacy in stroke prevention, an improved safety profile, and improved user-friendliness. Dabigatran was the first of the agents to be widely available, and in the RE-LY study, dabigatran (150 mg dose) showed superiority to warfarin in preventing ischemic stroke and a significant reduction in intracranial bleeding. Rivaroxaban was studied in the ROCKETAF trial, and with once daily dosing, it showed noninferiority to warfarin in preventing stroke with a significant reduction in intracranial bleeding. The ARISTOTLE trial showed apixaban was superior to warfarin for stroke prevention, significantly reduced all major bleeding, and resulted in a significant reduction in all-cause mortality. While all three trials have important limitations, they were very large randomized trials with more than 14,000 patients each and show a clear overall net clinical benefit when compared with warfarin. Key features of the drugs as well as an individual's preferences and stability on warfarin will help guide the ultimate drug choice for any given patient, but these newer anticoagulant agents are likely to usher in a new era in stroke prevention in atrial fibrillation.",
keywords = "Anticoagulation, Apixaban, Atrial fibrillation, Dabigatran, Intracranial hemorrhage, Rivaroxaban, Stroke, Warfarin",
author = "Bhimani, {Ashish A.} and Mauricio Hong",
year = "2013",
doi = "10.2174/15748871113089990044",
language = "English (US)",
volume = "8",
pages = "78--85",
journal = "Reviews on Recent Clinical Trials",
issn = "1574-8871",
publisher = "Bentham Science Publishers B.V.",
number = "2",

}

TY - JOUR

T1 - New alternative anticoagulants in atrial fibrillation

T2 - The move beyond warfarin

AU - Bhimani, Ashish A.

AU - Hong, Mauricio

PY - 2013

Y1 - 2013

N2 - Given the increasing prevalence of atrial fibrillation, the need for safe and effective stroke prophylaxis will continue to rise. Warfarin has been around for many years and has proven efficacy in preventing stroke, but it has major limitations due to its variable dosing, food and drug interactions, and requirement for regular monitoring. Newer agents which include dabigatran, rivaroxaban, and apixaban have recently or will soon be available and may provide an improved efficacy in stroke prevention, an improved safety profile, and improved user-friendliness. Dabigatran was the first of the agents to be widely available, and in the RE-LY study, dabigatran (150 mg dose) showed superiority to warfarin in preventing ischemic stroke and a significant reduction in intracranial bleeding. Rivaroxaban was studied in the ROCKETAF trial, and with once daily dosing, it showed noninferiority to warfarin in preventing stroke with a significant reduction in intracranial bleeding. The ARISTOTLE trial showed apixaban was superior to warfarin for stroke prevention, significantly reduced all major bleeding, and resulted in a significant reduction in all-cause mortality. While all three trials have important limitations, they were very large randomized trials with more than 14,000 patients each and show a clear overall net clinical benefit when compared with warfarin. Key features of the drugs as well as an individual's preferences and stability on warfarin will help guide the ultimate drug choice for any given patient, but these newer anticoagulant agents are likely to usher in a new era in stroke prevention in atrial fibrillation.

AB - Given the increasing prevalence of atrial fibrillation, the need for safe and effective stroke prophylaxis will continue to rise. Warfarin has been around for many years and has proven efficacy in preventing stroke, but it has major limitations due to its variable dosing, food and drug interactions, and requirement for regular monitoring. Newer agents which include dabigatran, rivaroxaban, and apixaban have recently or will soon be available and may provide an improved efficacy in stroke prevention, an improved safety profile, and improved user-friendliness. Dabigatran was the first of the agents to be widely available, and in the RE-LY study, dabigatran (150 mg dose) showed superiority to warfarin in preventing ischemic stroke and a significant reduction in intracranial bleeding. Rivaroxaban was studied in the ROCKETAF trial, and with once daily dosing, it showed noninferiority to warfarin in preventing stroke with a significant reduction in intracranial bleeding. The ARISTOTLE trial showed apixaban was superior to warfarin for stroke prevention, significantly reduced all major bleeding, and resulted in a significant reduction in all-cause mortality. While all three trials have important limitations, they were very large randomized trials with more than 14,000 patients each and show a clear overall net clinical benefit when compared with warfarin. Key features of the drugs as well as an individual's preferences and stability on warfarin will help guide the ultimate drug choice for any given patient, but these newer anticoagulant agents are likely to usher in a new era in stroke prevention in atrial fibrillation.

KW - Anticoagulation

KW - Apixaban

KW - Atrial fibrillation

KW - Dabigatran

KW - Intracranial hemorrhage

KW - Rivaroxaban

KW - Stroke

KW - Warfarin

UR - http://www.scopus.com/inward/record.url?scp=84888062952&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84888062952&partnerID=8YFLogxK

U2 - 10.2174/15748871113089990044

DO - 10.2174/15748871113089990044

M3 - Article

VL - 8

SP - 78

EP - 85

JO - Reviews on Recent Clinical Trials

JF - Reviews on Recent Clinical Trials

SN - 1574-8871

IS - 2

ER -